Oracle and Cognizant to Accelerate Study Startup in Clinical Trials

Life Sciences leaders integrate technologies to streamline clinical study startup-process and trial site collaboration to help speed time to market for new therapies

Austin, Texas—January 25, 2021 To help sponsors and contract research organizations (CROs) get clinical trial sites up and running much faster, Cognizant's Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, is now integrated with Oracle Health Sciences. By standardizing administrative tasks and processes with one unified system, sponsors and CROs can reduce study startup time, increase collaboration, and streamline the management of clinical trials. A global leader in business and technology services, Cognizant is a member of Oracle PartnerNetwork (OPN).

"Being able to stay connected, reduce administrative work, and stand up clinical trials quickly is paramount, especially as the world faces the pandemic and must maneuver around social distancing guidelines," said Srinivas Shankar, Global Head of Life Sciences, Cognizant. "Since 2016, Cognizant has offered its Shared Investigator Platform, transforming how researchers and medical professionals collaborate across sites. Now with over 130,000 users across 100 countries, this digital solution, in collaboration with Oracle, is helping bridge digital technology and life sciences to speed the process for bringing new therapies to market."

Cognizant and Oracle, both recognized industry leaders, have combined the SIP solution and study startup offerings to address these site challenges and deliver unique value in the initialization of studies, collaboration, and management.

By combining the Oracle and Cognizant systems, CROs and sponsors will be able to ease common burdens, such as manual, paper processes, navigate disparate technology systems, and eliminate multiple log-ins. For sites, the integration provides a centralized site profile that is maintained by the site and can be leveraged across multiple studies by sponsors and CROs. This centralization, plus the ability to use a single log-in, will save both time and costs.

"Sites are eager for simplification of systems that will increase efficiency across multiple studies and reduce administrative burden," said Casey Orvin, honorary president of the Society for Clinical Research Sites (SCRS). "When solution providers create products that sites can access across study programs, it's a win for sponsors and CROs, sites, and ultimately for patients."

"Together, Oracle and Cognizant have worked with more than 200,000 investigative sites globally. This level of experience and expertise is unmatched," said Sujay Jadhav, Global Vice President, Product Management, Oracle Health Sciences. "The combination of Oracle's optimized workflows for regulatory and organizational compliance, together with our advanced predictive capabilities based on machine learning with Cognizant's site-centric platform will make the overall management of study startup operations across multiple sites easier and more cost effective."

Sponsors and CROs can benefit from:

- Analytics and dashboards that harmonize processes and common documents (e.g., form 1572, CV, financial disclosure) leveraged across studies.
- Increased data reliability, transparency, and regulatory compliance with pre-configured site workflows to improve study quality and automate workflows for the management of contacting sites and collecting site documentation for IRB/EC submissions.
- Optimized workflows to increase efficiencies in starting clinical trials by accelerating timelines and reducing administrative processes.
- Not having to manage related IT, as real-time integration is maintained by Oracle and Cognizant.

For investigative sites, the integration can:

- Eliminate multiple login maintenance and associated costs via secure single sign-on (SSO), which links site personnel quickly and easily to study startup technologies and tools.
- Provide a consistent and centralized experience by using site profile information that is repeatedly requested by sponsors and CROs, maintained by the site, and leveraged across multiple studies.

Additional Resources

Join the Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup Webcast to learn more on Jan. 26, 2020. Register here.

For more information about Oracle study startup applications visit:
https://www.oracle.com/industries/life-sciences/clinical-research/products/

For more information about Cognizant Shared Investigator Platform visit:

https://www.cognizant.com/shared-investigator-platform

Contact Info

Judi Palmer
Oracle
judi.palmer@oracle.com
+1 650 784 7901

Joshua Blumenthal
Cognizant
joshua.blumenthal@cognizant.com
+1 267.244.2841

About Cognizant
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.

About Oracle Health Sciences
As a leader in Life Sciences cloud technology, Oracle Health Sciences' Clinical One and Safety One are trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance. With over 20 years' experience, Oracle Health Sciences is committed to supporting clinical development, delivering innovation to accelerate advancements, and empowering the Life Sciences industry to improve patient outcomes. Oracle Health Sciences. For life.

About Oracle
Oracle offers suites of integrated applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

---

https://news.cognizant.com/2021-01-25-Oracle-and-Cognizant-to-Accelerate-Study-Startup-in-Clinical-Trials